Establishing a Dedicated Lung Cancer Biobank at the University Center Hospital of Nice (France). Why and How?
- Creators
- Washetine, Kevin
- Heeke, Simon
- Bonnetaud, Christelle
- Kara-Borni, Mehdi
- Ilié, Marius
- Lassalle, Sandra
- Butori, Catherine
- Long-Mira, Elodie
- Marquette, Charles Hugo
- Cohen, Charlotte
- Mouroux, Jérôme
- Selva, Eric
- Tanga, Virginie
- Bence, Coraline
- Félix, Jean-Marc
- Gazoppi, Loic
- Skhiri, Taycir
- Gormally, Emmanuelle
- Boucher, Pascal
- Clement, Bruno
- Dagher, Georges
- Hofman, Véronique
- Hofman, Paul
- Others:
- Centre Hospitalier Universitaire de Nice (CHU Nice)
- Institut de Recherche sur le Cancer et le Vieillissement (IRCAN) ; Université Nice Sophia Antipolis (1965 - 2019) (UNS) ; COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA)
- Nutrition, Métabolismes et Cancer (NuMeCan) ; Institut National de la Recherche Agronomique (INRA)-Université de Rennes 1 (UR1) ; Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Institut National de la Santé et de la Recherche Médicale (INSERM)
- French Government (National Research Agency, ANR) through the "Investments for the Future" LABEX SIGNALIFE [ANR-11-LABX-0028-01]; Canceropole PACA; la Ligue Departementale 06 de Lutte contre le Cancer; la Direction Generale de l'Offre des Soins; l'Universite Cote d'Azur; et le Conseil Departemental des Alpes Maritimes
- ANR-11-LABX-0028,SIGNALIFE,Réseau d'Innovation sur les Voies de Signalisation en Sciences de la Vie(2011)
Description
Lung cancer is the major cause of death from cancer in the world and its incidence is increasing in women. Despite the progress made in developing immunotherapies and therapies targeting genomic alterations, improvement in the survival rate of advanced stages or metastatic patients remains low. Thus, urgent development of effective therapeutic molecules is needed. The discovery of novel therapeutic targets and their validation requires high quality biological material and associated clinical data. With this aim, we established a biobank dedicated to lung cancers. We describe here our strategy and the indicators used and, through an overall assessment, present the strengths, weaknesses, opportunities and associated risks of this biobank.
Abstract
International audience
Additional details
- URL
- https://hal-univ-rennes1.archives-ouvertes.fr/hal-01834086
- URN
- urn:oai:HAL:hal-01834086v1
- Origin repository
- UNICA